Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 7 Results

Title
Intervention Indication Therapeutic Area Year Actions
CC-486 for angioimmunoblastic T-cell lymphoma Azacitidine (Vidaza; CC-486) Angioimmunoblastic T-cell Lymphoma (AITL) Haematological Cancer and Lymphomas 2020 View  |  Download
CC-486 for maintenance therapy in acute myeloid leukaemia Azacitidine (Vidaza; CC-486) Acute myeloid leukaemia (AML) Haematological Cancer and Lymphomas 2020 View  |  Download
Ivosidenib with azacitidine for previously untreated acute myeloid leukaemia with an IDH1 mutation Azacitidine (Vidaza; CC-486) , Ivosidenib (Tibsovo; AG-120) Acute myeloid leukaemia (AML) Haematological Cancer and Lymphomas 2022 View  |  Download
Magrolimab in addition to azacitidine for myelodysplastic syndromes - First-line Azacitidine (Vidaza; CC-486) , Magrolimab (Hu5F9-G4) Myelodysplastic syndrome (MDS) Haematological Cancer and Lymphomas 2021 View  |  Download
Pevonedistat in addition to azacitidine for Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Low Blast Acute Myeloid Leukemia – first-line Azacitidine (Vidaza; CC-486) , Pevonedistat (MLN-4924; TAK-924) Acute myeloid leukaemia (AML) , Chronic myelomonocytic leukaemia (CMML) , Myelodysplastic syndrome (MDS) Haematological Cancer and Lymphomas 2020 View  |  Download
Sabatolimab in addition to azacitidine for myelodysplastic syndromes – first-line Azacitidine (Vidaza; CC-486) , Sabatolimab (MBG453) Chronic myelomonocytic leukaemia (CMML) , Myelodysplastic syndrome (MDS) Haematological Cancer and Lymphomas 2021 View  |  Download
Venetoclax in combination with azacitidine for myelodysplastic syndrome Azacitidine (Vidaza; CC-486) , Venetoclax (Venclyxto; ABT-199; Venclexta; GDC-0199) Myelodysplastic syndrome (MDS) Haematological Cancer and Lymphomas 2023 View  |  Download
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications